← My Journey

Investment thesis · ANTHEM · v1 · effective 2026-07-14

Restocking recovery and CRDMO capacity ramp

Anthem's FY26 slowdown must prove to be temporary destocking: CRDMO orders should recover, Unit III should contribute and molecules should keep progressing toward commercialisation. Unit IV and new modalities add upside, but the high valuation leaves little tolerance for weak utilisation or delayed growth.

Live levels and fundamentals →Read the full deep dive →

Core thesis

The FY26 slowdown was substantially a temporary customer-destocking cycle; recovery, differentiated fermentation capabilities and new capacity should restore durable CRDMO growth as molecules progress toward commercialisation.

Horizon: FY27–FY29, reviewed at each result and material capacity update

Thesis legs

• Existing CRDMO platform proven
  Integrated chemistry and fermentation capabilities, commercial molecules and high margins establish a differentiated operating base.
• Restocking recovery in-progress
  The FY26 slowdown was substantially cyclical and should unwind through renewed customer orders rather than require a new end-market thesis.
• Pipeline and new modalities optionality
  Phase 3 progression, GLP-1, ADC and other advanced modalities can deepen growth, but unattributed end-market forecasts are not Anthem revenue.
• Unit IV unproven
  The large expansion can extend the runway only if commissioning, utilisation and returns follow customer demand without damaging capital efficiency.

What must happen

• Subsequent results confirm that customer restocking produces a durable revenue recovery rather than a one-quarter rebound.
• Unit III fermentation and other recently added capacity make a measurable contribution through FY27.
• The Phase 3 pipeline progresses toward commercial production while Unit IV spending remains economically and financially controlled.

What supports it

• Integrated discovery-to-commercial CRDMO capabilities and fermentation capacity form the claimed operating moat.
• Near-zero leverage and strong historical returns on equity provide capacity-investment resilience.

What would break it

• Revenue fails to recover after the stated end of destocking or management repeatedly resets the explanation.
• Material molecule failures, withdrawals or customer losses undermine the commercial pipeline.
• Capacity ramps without utilisation, cash returns or credible customer demand.
• DavosPharma dependence, an adverse regulatory inspection or scientific-talent loss materially disrupts operations.
• Earnings growth fails to support the high valuation over the thesis horizon.

Known risks

• Product and customer concentration
• DavosPharma channel and related-party dependence
• Clinical and commercialisation failure
• Capacity execution
• Regulatory inspection
• Scientific-talent retention
• Valuation

Valuation frame

As of 2026-07-14: ₹750 per share, ₹42,524 crore market cap.

The illustrative FY27 case is not company guidance. At this valuation the committee must demand evidence of durable restocking, commercial molecule progression and profitable capacity utilisation; sector enthusiasm or pipeline market size cannot substitute for attributable earnings.

What I monitor

• Quarterly CRDMO revenue growth and evidence of customer restocking
• CRDMO and speciality-ingredients revenue and EBITDA mix
• Commercial, Phase 3 and early-stage molecule counts and movements
• Unit III utilisation and incremental revenue contribution
• Unit IV capex, commissioning schedule and customer-backed utilisation
• Top-customer and top-product concentration
• DavosPharma-related revenue, terms and related-party disclosures
• Regulatory inspection outcomes and scientific-employee attrition
• Operating cash flow, return on capital and leverage through expansion

Sources

• Investor-authored Anthem deep dive
• Q4 and FY26 earnings-call transcript
• IPO prospectus and exchange filings

My own reasoning for holding this stock, written while learning. Not investment advice.